Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

Shanghai Kechow Pharmaceuticals

Status and phase: Enrolling; Phase 2

Conditions: CRC

Treatments: Drug: HL-085; Drug: Vemurafenib

Study type: Interventional

Funder types: Industry

Identifiers

NCT05233332

HL-085-201

Details and patient eligibility

About

The study consists of the two parts, phase IIa and phase IIb.

Full description

The study consists of the two parts, phase IIa and phase IIb. Phase IIa study is to assess the safety and the antitumor activity in patients with mCRC and to recommend reasonable dosage regimen of HL-085 for phase IIb study. Phase IIb is a pivotal study to evaluate HL-085 plus Vemurafenib in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting.

Enrollment: 186 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent prior to enrollment；
• Adults 18 years of age or older, male or female;
• Histologically- or cytologically-confirmed CRC that is metastatic disease, and a) progression of disease or intolerance after line 1 or line 2 therapy，or inappropriate for line 1 therapy (for phase Ⅱa); b) progression of disease or intolerance after line 1 or line 2 therapy (for phase Ⅱb);
• Patient must have measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version 1.1);
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
• Life expectancy ≥ 3 months;
• Able to take the medicine orally;
• Adequate bone marrow and organ function.

Exclusion criteria

• Prior treatment with any RAS inhibitors, RAF inhibitors, or MEK inhibitors;
• History or screening evidence of retinal diseases;
• Impaired cardiovascular function or clinically significant cardiovascular and cerebrovascular diseases;
• Previous or current neuromuscular diseases that is associated with CK elevation (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy, rhabdomyolysis syndrome);
• Impaired liver function, defined as Child-Pugh Class B or C;
• Toxicity has not recovered to grade 0 or 1 from prior anticancer therapy (except for alopecia, pigmentation, and grade 2 chemotherapy-related neurotoxicity);
• Use of any medications or foods that are strong inhibitors or inducers of cytochrome P450 (CYP) 3A4/5 within 7 days prior to the start of study treatment or during the study period, , drugs with a narrow therapeutic window for CYP1A2 metabolism.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

186 participants in 4 patient groups

phase IIa: HL-085 in Subjects With BRAF V600E-Mutated CRC

Experimental group

Description:

12mg BID HL-085

Treatment:

Drug: HL-085

phase IIa: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC

Experimental group

Description:

12mg BID HL-085+720mg BID Vemurafenib

Treatment:

Drug: HL-085

Drug: Vemurafenib

phase IIa: HL-085+Vemurafenib in Subjects With RAS or other BRAF-Mutated or MEK1/2-Mutated CRC

Experimental group

Description:

12mg BID HL-085+720mg BID Vemurafenib

Treatment:

Drug: HL-085

Drug: Vemurafenib

phase IIb: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC

Experimental group

Description:

12mg BID HL-085+720mg BID Vemurafenib

Treatment:

Drug: HL-085

Drug: Vemurafenib